CardiAQ Valve Technologies Raises $37.3M Series B

Nov. 29, 2012 : CardiAQ™ Valve Technologies, Inc., a privately held medical device company developing technologies for percutaneous mitral heart valve replacement, announced today that it received $37.3 million in funding in its second round of equity financing. OrbiMed led the round and was joined by Versant Ventures, Advent Life Sciences and existing investors. The funding, which incorporates conversion of a 2011 bridge financing, will be used to further validate the Company’s TMVI technology and is expected to carry the Company through its feasibility and CE mark clinical trials. Concurrent with the financing, David Bonita,M.D., and Vince Burgess have joined the board of directors representing OrbiMed.

 

Press Release